SCHEMBL691779

SCHEMBL691779

CC(CCN=C=S)=S=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7753271 0.88 TRPA1 (0.45)
SCHEMBL27521725 0.84 TRPA1 (0.48)
SCHEMBL18581783 0.84 TRPA1 (0.48)
SCHEMBL27593695 0.84 TRPA1 (0.48)
SCHEMBL27593694 0.84 TRPA1 (0.48)
SCHEMBL27575394 0.84 TRPA1 (0.48)
SCHEMBL27603964 0.77
SCHEMBL14489602 0.75
SCHEMBL2040306 0.72
SCHEMBL25333148 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 EP disclosed
EP-2421524-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS INC (US) 2018-08-08 EP disclosed
EP-2421524-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Elcelyx Therapeutics, Inc. (US) 2012-02-29 EP disclosed
WO-2010123930-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2010-10-28 WO disclosed
EP-1069819-A1 METHOD FOR SELECTIVE INCREASE OF THE ANTICARCINOGENIC GLUCOSINOLATES IN $i(BRASSICA SP.) Plant Bioscience Limited (GB) 2001-01-24 EP disclosed
WO-1999052345-A1 METHOD FOR SELECTIVE INCREASE OF THE ANTICARCINOGENIC GLUCOSINOLATES IN $i(BRASSICA SP.) PLANT BIOSCIENCE LIMITED (GB) 1999-10-21 WO disclosed